Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Relugolix
Indication/Tumor Type prostate cancer
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable Relugolix Phase III Actionable In a Phase III trial (HERO), Relugolix (TAK-385) demonstrated superior serum testosterone suppression and maintenance of castration compared to Lupron (leuprolide) (96.7%, 601/622 vs 88.8%, 273/308, p<0.0001) in patients with androgen-sensitive advanced prostate cancer (PMID: 32469183; NCT03085095). 32469183
Unknown unknown prostate cancer not applicable Relugolix Phase II Actionable In a Phase II trial, Relugolix (TAK-385) resulted in decreased testosterone levels and greatly reduced prostate specific antigen levels after 24 weeks in prostate cancer patients (J Clin Oncol 34, 2016 (suppl 2S; abstr 200)). detail...
PubMed Id Reference Title Details
Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts). Full reference...
(32469183) Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Full reference...